Prepare for Manipal Entrance Test with ease with Edugraph Colleges! Our exam page offers detailed information on the syllabus, helping you stay ahead of the competition. Join us today and prepare with ...

From the sustainable agronomic practices in improving cotton productivity to the opportunities and challenges for the Indian ...

The RSSB has released the Rajasthan CET 2026 syllabus. Exam would be conducted in offline mode with 120 objective-type ...

The CBSE Class 12 Biotechnology syllabus for the 2026-27 academic year remains same as the previous year. It outlines the required chapters and subjects, assessment criteria, project work guidelines, ...

Two federal lawmakers have introduced a bill seeking to apply the review requirements of the Comprehensive Outbound Investment National Security (COINS) Act to investments in Chinese biotechnology.

The wide-ranging geopolitical rivalry between Beijing and Washington could soon expand into biotechnology, raising the prospect of fresh tensions even as American pharmaceutical firms have turned to ...

Biopharma companies appear to be more willing to go public after a long drought. Just this week, GLP-1 developer Kailera Therapeutics and proteomics company Alamar Biosciences launched IPO roadshows ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch ...

Marc Cummings, president and CEO of Life Science Washington, speaking at a one-day forum focused on AI-driven biotech that was held in Seattle in October 2025. (Life Science Washington Photo) Seattle ...

Biotech stocks saw a major rebound in 2025, with key indexes significantly outperforming the S&P 500. Private investment in longevity science doubled in 2024, highlighting growing interest in ...

There are hundreds of biotechnology companies today that have never commercialized a drug. For many years, the standard approach in the industry has been to advance the science, prove the asset, and ...